Wall Street Researcher
PRESSURE BIOSCIENCES INC
Highlights – CBD
These shares have bottomed recently on light volume. The 200 day M/A of $2.41 could be tested soon. Average daily volume is 30,000 shares for the same 200 day period .
A superior management team is driving these shares higher discovering new uses for their medical device – Ultra Shear Tech Platform
We feel that a BUYING OPPORTUNITY is now at hand . All serious investors must place these shares on their BUY LIST and watch carefully for an UPSIDE BREAKOUT
Investor Contact – Gary Zwetchkenbaum- Plum Tree Consulting LLC –Cell : 516 – 455-7662 – EMAIL – firstname.lastname@example.org WATCH VIDEO
A recent press release by Pressure BioSciences Inc. OTCQBPBIO announcing a development in its cannabidiol (CBD) research program seems to have given industry watchers an indication of the company’s future.
Pressure BioSciences, a player in the development and sale of broadly enabling, pressure-based systems with applications across multiple industries, including nutraceuticals, pharmaceuticals, and biotechnology, has set its sights on being a dominant force in many of these industries. A recent expansion drive appears to support this intention
A New CBD Manufacturing Technology?
Pressure BioSciences Inc. (PBI) revealed in a press release that hemp-derived CBD processed with its patented Ultra Shear Technology™ (UST™) platform produced high-quality, water-soluble nanoemulsions of CBD oil in water. The technology has now demonstrated visual and analytical stability 18 months after production and baseline testing.
From all indications, PBI feels that this revelation is welcome news and a game-changer for CBD and the rest of the cannabinoid industry. For some years now, a significant obstacle to CBD’s commercial advancement has been its insolubility in water and poor absorption (bioavailability) by the human body.
The World Health Organization (WHO) estimates that as little as 6% of CBD is absorbed via current oral delivery routes. Thus, most ingested CBD is wasted, passing through the body without being absorbed.
This impediment engendered interest in the development a truly water-soluble CBD to deliver efficient dosing, absorption, bioavailability and benefit from CBD products — foods, beverages,cosmetics, and therapeutics. PBI seems to have surmounted that problem.
For years, CBD oil has been studied for its potential ability to ease the symptoms of many health conditions — including neurological disorders. It is a widely popular therapeutic for the relief of anxiety, depression and PTSD, as well as chronic inflammatory and neuropathic pain.
Early research suggests that CBD reduces spasticity in multiple sclerosis and may lessen the severity of neurological symptoms associated with Alzheimer’s Disease, Parkinson’s disease and schizophrenia. CBD is under investigation as a palliative adjunctive therapy in cancer.
A Growth Opportunity For PBI?
Dr. Alexander V. Lazarev, chief science officer of PBI, explained that “nanoemulsions, liposomes and solid lipid nanoparticles present many exciting opportunities as pharmaceutical and nutraceutical delivery systems. The smaller the size of oil droplets or particles, the better the stability and bioavailability of these preparations.”
Commercial UST System
Droplet size is a key determinant of accurate dosing and absorption, and an exciting benefit of the UST technology platform. According to Gary B. Smejkal, a senior research scientist at PBI, “the intense fluid shearing in UST progressively decreases oil droplet size with each cycle, making the method highly tunable.” The platform can produce CBD nanoemulsions of uniform 30 to 40 nm droplet sizes that are stable at room temperature for at least 18 months, Smejkal added.
Giving a forecast of the breakthrough technology, John B. Hollister, director of sales and marketing at PBI, revealed that it offers the potential to revolutionize the rapidly growing cannabis market in food, beverages, and therapeutics.
Hollister was optimistic that PBI’s historic stability milestone positions PBI for rapid customer adoption of the UST nanoemulsion system upon commercial release, planned for the second half of 2022.
Neither PSN or WSR nor its owners, members, officers, directors, partners, consultants, nor anyone involved in the publication of this website, is a registered investment adviser or broker-dealer or associated person with a registered investment adviser or broker-dealer and none of the foregoing make any recommendation that the purchase or sale of securities of any company profiled in the PSN or WSR website is suitable or advisable for any person or that an investment or transaction in such securities will be profitable. The information contained in the PSN or WSR website is not intended to be, and shall not constitute, an offer to sell nor the solicitation of any offer to buy any security. The information presented in the PSN or WSR website is provided for informational purposes only and is not to be treated as advice or a recommendation to make any specific investment. Please consult with an independent investment adviser and qualified investment professional before making an investment decision. Writer charges PBIO a fee of $950 per month . All Reports are reviewed for accuracy and concur that any conclusions made are reasonable expectations. The term Buy List referring to a Watch List and not a recommendation to buy . Each individual has their own risk level and should know their risk level and act accordingly